Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition - Wikidata - thesis-toulmin - TriplyDB

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

http://www.wikidata.org/entity/Q28143799

about

Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?beta-Amyloid degradation and Alzheimer's disease The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?Acyl peptide hydrolase, a serine proteinase isolated from conditioned medium of neuroblastoma cells, degrades the amyloid-beta peptide ApoE promotes the proteolytic degradation of Abeta Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele Diabetes Mellitus Induces Alzheimer's Disease Pathology: Histopathological Evidence from Animal Models Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease NLRP3 inflammasome: activation and regulation in age-related macular degeneration Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies Intracellular cleavage of amyloid β by a viral protease NIa prevents amyloid β-mediated cytotoxicity Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease From ARB to ARNI in Cardiovascular Control Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain Neurochemical profile of dementia pugilistica Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD)Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions New function for an old enzyme: NEP deficient mice develop late-onset obesity Alzheimer Disease and Its Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Need for Therapeutics.Distinct binding sites in the structure of alpha 2-macroglobulin mediate the interaction with beta-amyloid peptide and growth factors.Pyrrolidine dithiocarbamate attenuates brain Aβ increase and improves long-term neurological outcome in rats after transient focal brain ischemia.Traditional used Plants against Cognitive Decline and Alzheimer Disease.Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations Alzheimer disease models and human neuropathology: similarities and differences Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice Improved learning and memory in aged mice deficient in amyloid beta-degrading neutral endopeptidase.Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease.In vivo turnover of tau and APP metabolites in the brains of wild-type and Tg2576 mice: greater stability of sAPP in the beta-amyloid depositing mice Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity.Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin.Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro

P2860

Q21202832-E24C85B0-E467-4594-AFCB-9F9CD3A0C1AD Q21284467-5BBF7321-E55D-4E99-A3DB-9DA386162EB6 Q21296650-2ED618D0-BF3D-4B1F-8E74-4909C188DBF0 Q24293938-D00BBC0F-4272-4D55-B529-7E06B520E8DB Q24651102-FD0F27C3-3D17-41A7-B3BF-910281E85822 Q24684471-C2765644-E0B3-4223-82EA-1A99E97A4880 Q26750648-EDC71D49-E61C-4E4E-9CF9-0ED142B06149 Q26862901-C19A2292-9593-4C76-9145-145751430D77 Q26995315-C92178DB-39BC-4B4E-8766-E7CBB7B26B85 Q27001177-7ECEFD57-5899-4866-BBAF-AD0017ACD28C Q27005843-9292598D-C124-4576-891E-0C7EC695743B Q27012755-E7F00FC6-1816-48D9-B7E3-7806855DE731 Q27324934-F84EDDA6-6C04-43F7-8E81-0426DB929AED Q27437619-C07D60B1-2522-4224-B362-E2C0F28F98CD Q28073372-710D7A47-6F84-468A-8727-10A2E4E4B6AE Q28081678-1C85E394-AA6E-40A5-B09C-5D8E8388CE4E Q28216644-0502048A-23C4-4A84-8BF4-CA8A9450B1FD Q28366524-9562FBAE-0B32-40E0-BC14-224B61346221 Q28384455-33827E90-D4B0-4101-ABDE-962C5F2EA0E3 Q28505860-5A3F3892-4560-4153-89D4-4FD669D13F57 Q28568146-6735E317-B1B9-4D8D-AFA4-7DE478D054E8 Q28570444-BE8B962D-A64C-4AEE-AAB9-92491A001743 Q28749264-A9DC78FC-DE5E-4053-A39C-0A9A3167F67E Q30244736-2EDD3BE3-C850-496E-98C5-C4931349C418 Q30308620-CAB2B1D8-65C4-4C18-A498-9EFA08D9382E Q30423207-9C92B7D8-7C03-424D-AF38-C45D6DF767E1 Q30474547-ACCA2706-4BA1-45B4-99D6-64208F7AE2DB Q30491040-D677F961-C44A-4064-A9B7-A82F7CC8EEDB Q30499574-77D45D97-D694-46C1-9D41-7ED511EE2C29 Q30533859-FCC05566-11A8-4393-96E9-A6A1B6DB662D Q30668465-A1EDEFAA-2CA8-4C2F-AC2A-4D2B34377DF3 Q30833707-8BCA593C-380F-4513-A5D7-A5380134DBBF Q33262322-07E3BA35-E982-46D3-B470-2C77986D08B5 Q33384861-BC325928-9424-49CD-855B-EC0B16E84079 Q33412126-CE1872D6-6760-42DE-8E94-08368ED5E736 Q33444709-D84F0B1F-04C0-4339-BDD4-F60D4B12E58E Q33505668-99CCB823-2D9E-4E7A-9AC0-CB9A5E11E712 Q33536103-531C5725-CAEE-4765-9AF1-3AF3A776A831 Q33569877-13C8F3C3-3DF3-4ADC-B0C7-72584604E268 Q33643056-271BB74F-474D-456D-BADB-30EFB9D12303

P2860

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

http://www.wikidata.org/entity/Q28143799

description

2000 nî lūn-bûn

@nan

2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Identification of the major Ab ...... al and pathological deposition

@ast

Identification of the major Ab ...... al and pathological deposition

@en

Identification of the major Ab ...... al and pathological deposition

@nl

type

label

Identification of the major Ab ...... al and pathological deposition

@ast

Identification of the major Ab ...... al and pathological deposition

@en

Identification of the major Ab ...... al and pathological deposition

@nl

prefLabel

Identification of the major Ab ...... al and pathological deposition

@ast

Identification of the major Ab ...... al and pathological deposition

@en

Identification of the major Ab ...... al and pathological deposition

@nl

P1433

Q28143799-04455CE5-7F70-43D2-8824-4C4F25589B82

P1476

Q28143799-B3C251A7-3C04-428C-ABC9-B4E018B2A4F7

P2093

Q28143799-2B73DFF7-608E-4112-86B7-EA7A323CAB72

Q28143799-45B3E63E-71F9-4E83-8118-13EB74BD4772

Q28143799-51D911E6-A6D6-4E8A-B848-E745D4543786

Q28143799-56C6F200-E132-436C-A7D2-718697A882C7

Q28143799-891A0F7D-54DB-46F2-81E6-0118AF9F84B9

Q28143799-9644B7D3-C551-4949-B9ED-4428DA0A2815

Q28143799-D29E1210-98F9-4188-8287-8BF57A253D26

Q28143799-D43B6ADE-D530-4F89-9236-44197AAE69EF

Q28143799-D93D0AE9-9250-4D1B-9D81-8BE6CAD54FB0

Q28143799-E5756660-D3AA-49D5-BE81-348FE0466DA5

P2888

Q28143799-5F07023C-9E63-42D1-8766-C0F8DE751118

P304

Q28143799-EAA1F48C-2AB4-4CCB-866A-499586C9E637

P31

Q28143799-AEE112EB-4EA3-49E7-AEF3-6421635AA76A

P3181

Q28143799-B48F6FAF-0109-4AE8-8E04-13A62CF2D755

P356

Q28143799-354655E7-3C28-4B55-922B-B26378BB4DF0

P407

Q28143799-26CD31C4-08BC-47DA-B854-43A71CCC509C

P433

Q28143799-B6DE8382-4D87-4123-A615-0CA1A8D50EB3

P478

Q28143799-0D1A026A-AF02-4134-9B74-FEAB6AF4852F

P577

Q28143799-88B1336D-B111-4C0E-BD3C-2F569CBA3DEC

P5875

Q28143799-5B005936-82B5-4F60-B814-0A8D26DF3B4E

P698

Q28143799-92DF50D1-C1EE-4A2D-9805-401F20CB994E

P921

Q28143799-DB496106-4647-42BF-A048-58A7AC69185C

P3181

P356

P1433

Nature Medicine

P1476

Identification of the major Ab ...... al and pathological deposition

@en

P2093

E Hama

http://www.w3.org/2001/XMLSchema#string

E Hosoki

http://www.w3.org/2001/XMLSchema#string

H J Lee

http://www.w3.org/2001/XMLSchema#string

K Watanabe

http://www.w3.org/2001/XMLSchema#string

M Kawashima-Morishima

http://www.w3.org/2001/XMLSchema#string

M Sekiguchi

http://www.w3.org/2001/XMLSchema#string

N Iwata

http://www.w3.org/2001/XMLSchema#string

S Tsubuki

http://www.w3.org/2001/XMLSchema#string

T C Saido

http://www.w3.org/2001/XMLSchema#string

Y Sekine-Aizawa

http://www.w3.org/2001/XMLSchema#string

P2888

P304

143-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2475077

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/72237

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2000-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12659899

http://www.w3.org/2001/XMLSchema#string

P698

10655101

http://www.w3.org/2001/XMLSchema#string

P921